List of Cosela drug patents

Cosela is owned by G1 Therap.

Cosela contains Trilaciclib Dihydrochloride.

Cosela has a total of 10 drug patents out of which 0 drug patents have expired.

Cosela was authorised for market use on 12 February, 2021.

Cosela is available in powder;intravenous dosage forms.

Cosela can be used as a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer, a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer.

Drug patent challenges can be filed against Cosela from February, 2025.

The generics of Cosela are possible to be released after 14 March, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8598186 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US9957276 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US10189849 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US8598197 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10189850 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US10927120 G1 THERAP CDK inhibitors
Oct, 2031

(8 years from now)

US10085992 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(11 years from now)

US10966984 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(11 years from now)

US11040042 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(11 years from now)

US9487530 G1 THERAP Transient protection of normal cells during chemotherapy
Mar, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 12, 2026

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 12 February, 2021

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in